Narval
Narval creates synthetic antibody-mimetic proteins that enable localized, non-systemic treatment via mucosal and skin delivery. The company produces macrocyclic Antibody Mimetic Proteins (AMPs) by fusing CDR3 regions of single-domain shark antibodies onto a conoprotein scaffold from sea snails and optimizes candidates using AI and machine learning. Narval is a B2B biotech therapeutic platform combining protein engineering, macrocyclic synthetic proteins, and ML-driven drug design. Its AMPs are aimed at treating conditions of the eyes, lungs, and skin and are developed for rapid-response medical countermeasures, biodefense, animal health, and agricultural biosecurity. The approach targets affordable, flexible, and deployable immunotherapeutics that can be delivered mucosally for localized effect.
Narval
Narval creates synthetic antibody-mimetic proteins that enable localized, non-systemic treatment via mucosal and skin delivery. The company produces macrocyclic Antibody Mimetic Proteins (AMPs) by fusing CDR3 regions of single-domain shark antibodies onto a conoprotein scaffold from sea snails and optimizes candidates using AI and machine learning. Narval is a B2B biotech therapeutic platform combining protein engineering, macrocyclic synthetic proteins, and ML-driven drug design. Its AMPs are aimed at treating conditions of the eyes, lungs, and skin and are developed for rapid-response medical countermeasures, biodefense, animal health, and agricultural biosecurity. The approach targets affordable, flexible, and deployable immunotherapeutics that can be delivered mucosally for localized effect.